The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Remaining questions regarding mechanisms of response to immunotherapy in NSCLC
Michael MacManus, MBBch, MD, MRCP, Peter MacCallum Cancer Centre, Melbourne, Australia, explores the remaining questions regarding the use of immunotherapy in non-small cell lung cancer, highlighting the reasons why patients may or may not respond as well as the potential of Immuno-PET to identify responders. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
